Meredith McKean is an Oncology physician affiliated with Sarah Cannon. OpenAlex indexes 337 publications with 3,713 citations (h-index 25); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
250 25th Ave N Ste 200
Nashville, TN 37203
Telephone
615-986-4366Registry record last updated 27 Sept 2018.
Clinical trials
- Study of MTB-9655, an Inhibitor of ACSS2, in Patients With Advanced Solid Tumors
Sponsor: MetaboMed Inc
- Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
Sponsor: BicycleTx Limited
- Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
Sponsor: BicycleTx Limited
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
65 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Regeneron Pharmaceuticals, Inc.Program year202518 payments$22,747openpaymentsdata.cms.gov ↗
- Regeneron Healthcare Solutions, Inc.Program year202529 payments$10,190openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year20255 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
85.9%PD-1 inhibitor85.9%Pembrolizumab100%Part B, office-administered≥18 patientsSensory organs
11%Corticosteroid11%Dexamethasone sodium phosphate99%Dexamethasone1%Part D + Part B<11 patientsMetabolism & gastrointestinal
2.5%Serotonin-3 Receptor Antagonist2.3%Granisetron hydrochloride100%Part B, office-administered≥17 patientsCorticosteroid0.2%Prednisone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Denise Aysel Yardley
Sarah Cannon
Meredith Pelster, MD
Sarah Cannon
Mythili Shastry
Sarah Cannon
William Liggett, MD
Sarah Cannon
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”